Teva launches generic Olanzapine range in UK

Teva has announced the UK launch of a range of generic Olanzapine products for the treatment of schizophrenia.

Off-patent Olanzapine film-coated tablets and orodispersible tablets are being introduced bearing the Teva 360 livery in a variety of different strength specifications.

The product is a generic version of the branded product Zyprexa from Lilly, which is clinically proven to maintain improvement during continuation therapy for schizophrenia patients who have shown an initial response.

It is also indicated for the treatment of moderate to severe manic episodes and for the prevention of recurrence in patients with bipolar disorder.

Kim Innes, commercial director at Teva UK, said: "We are delighted to be bringing a generic version of this product to the UK market and at the same time further broaden our portfolio, which is the widest of any UK generics supplier."

This comes after fellow generics specialist Actavis also released an off-label version of Olanzapine at the end of last month.